Inventiva has added three executives to its C-suite as it prepares for a Phase III readout in 4Q26 for lanifibranor in metabolic dysfunction-associated steatohepatitis. The leadership changes include a new CFO, a refreshed legal leadership role, and a new chief people officer. Axel-Sven Malkomes, previously CFO of CureVac and an investment banker, will succeed Jean Volatier as CFO, with Volatier shifting to an EVP finance and corporate social responsibility role. Susan Coles returns as chief legal officer after serving in senior legal leadership positions previously including at Vivet Therapeutics, while Pamela Herbster joins as chief people officer. The personnel turnover comes as the company nears a late-stage inflection point; it also signals continued governance and execution focus for a candidate positioned in a category with high unmet need and increasing payer scrutiny.